Literature DB >> 12873923

A comparison of the costs and efficacy of ondansetron and dolasetron in the prophylaxis of postoperative vomiting in pediatric patients undergoing ambulatory surgery.

Olutoyin Olutoye1, Ellen C Jantzen, Rhonda Alexis, Donna Rajchert, Mark S Schreiner, Mehernoor F Watcha.   

Abstract

UNLABELLED: Postoperative vomiting (POV) after ambulatory surgery remains a major problem. We designed this study to determine the smallest dose of dolasetron equivalent to the Food and Drug Administration approved dose of ondansetron 100 micro g/kg IV, for the prophylaxis of POV in children undergoing surgery. In this double-blinded controlled study, 204 healthy ASA I-II children aged 2-12 yr, undergoing superficial ambulatory (day-case) surgery, were randomized to receive either ondansetron 100 micro g/kg IV, or dolasetron 45, 175, 350, or 700 micro g/kg IV during a standardized perioperative regimen. The primary end-point was the incidence of complete response, defined as the absence of POV symptoms. Costs were calculated from the perspective of the hospital using a previously described model. The incidence of early (0-6 h) and 24-h emesis was more frequent in the dolasetron 45 micro g/kg group compared with the dolasetron 350 and 700 micro g/kg groups and with the ondansetron group. Repeated POV occurred more often when dolasetron was used in a dose <350 micro g/kg. There were no significant differences in emesis rates between the dolasetron 175, 350, and 700 micro g/kg groups or between these groups and the ondansetron 100 micro g/kg group. The smallest dose of dolasetron with acceptable equivalent efficacy and patient satisfaction scores to ondansetron 100 micro g/kg was 350 micro g/kg. Institutional costs for managing POV were less with dolasetron 350 micro g/kg than with ondansetron. IMPLICATIONS: This randomized double-blinded dose-ranging study concluded that dolasetron, 350 micro g/kg IV, was the smallest dose that provided acceptable equivalent efficacy and patient satisfaction scores to ondansetron, 100 micro g/kg IV, for the prophylaxis of postoperative vomiting in children undergoing outpatient surgery. However, with this dose, the costs to the institution for managing postoperative vomiting were less.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12873923     DOI: 10.1213/01.ane.0000072706.09194.5e

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  4 in total

Review 1.  Therapeutic options for the prevention and treatment of postoperative nausea and vomiting: a pharmacoeconomic review.

Authors:  Jean Lachaine
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  Management of postoperative nausea and vomiting in children.

Authors:  Anthony L Kovac
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

3.  Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.

Authors:  Shivani V Gandhi; William Rodriguez; Mansoor Khan; James E Polli
Journal:  AAPS PharmSciTech       Date:  2014-02-21       Impact factor: 3.246

4.  Acute gastroenteritis: from guidelines to real life.

Authors:  Chung M Chow; Alexander Kc Leung; Kam L Hon
Journal:  Clin Exp Gastroenterol       Date:  2010-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.